StockNews.AISignal intelligence
Jasper Therapeutics, Inc. · NASDAQ · Healthcare
Browse public JSPR signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Jasper Therapeutics announced an all-stock acquisition of Kira Pharmaceuticals, paired with a private placement of about $132 million. The combined company out-licenses KP-301 and KP-402 to Mirador for $12 million upfront, funding operations through late-2028. The move expands the portfolio toward KP-104, briquilimab and KP-701, setting up multiple clinical milestones through 2027–2028.
View signal analysisJSPR stock dropped nearly 55% with high trading volume. Data from BEACON study indicated issues with drug product lot. Briquilimab showed effectiveness in certain cohorts despite concerns. Company halts asthma study and necessary cost-cutting measures are implemented. Further data is expected in Q4 2025 for the Phase 2b study.
View signal analysisJasper's SPOTLIGHT study shows 93% clinical response in cold urticaria patients. Briquilimab demonstrated good tolerability; no serious adverse events reported. Significant reductions in tryptase levels correlated with clinical responses. Jasper plans to provide full data by mid-2025, impacting future stock performance.
View signal analysis